KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Equivalents: 2010-2015

Historic Cash & Equivalents for Biocryst Pharmaceuticals (BCRX) over the last 5 years, with Sep 2015 value amounting to $46.6 million.

  • Biocryst Pharmaceuticals' Cash & Equivalents fell 61.52% to $46.6 million in Q3 2015 from the same period last year, while for Sep 2015 it was $46.6 million, marking a year-over-year decrease of 61.52%. This contributed to the annual value of $54.5 million for FY2014, which is 157.70% up from last year.
  • Latest data reveals that Biocryst Pharmaceuticals reported Cash & Equivalents of $46.6 million as of Q3 2015, which was down 39.27% from $76.8 million recorded in Q2 2015.
  • Over the past 5 years, Biocryst Pharmaceuticals' Cash & Equivalents peaked at $121.5 million during Q2 2014, and registered a low of $13.6 million during Q1 2014.
  • In the last 3 years, Biocryst Pharmaceuticals' Cash & Equivalents had a median value of $46.6 million in 2015 and averaged $51.3 million.
  • As far as peak fluctuations go, Biocryst Pharmaceuticals' Cash & Equivalents skyrocketed by 514.76% in 2014, and later crashed by 61.52% in 2015.
  • Biocryst Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $16.4 million in 2011, then increased by 27.04% to $20.9 million in 2012, then climbed by 1.31% to $21.2 million in 2013, then soared by 157.70% to $54.5 million in 2014, then crashed by 61.52% to $46.6 million in 2015.
  • Its Cash & Equivalents stands at $46.6 million for Q3 2015, versus $76.8 million for Q2 2015 and $48.4 million for Q1 2015.